In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Heart Leaflet Technologies Inc.

Latest From Heart Leaflet Technologies Inc.

As TAVI Advances, Adjunctive Devices Multiply

As researchers work to more fully understand the risks and durability of transcatheter aortic heart valve implantation (TAVI) procedures, device innovators are already attempting to engineer solutions to some of the more obvious areas of unmet need.

As researchers work to more fully understand the risks and durability of transcatheter aortic heart valve implantation (TAVI) procedures, device innovators are already attempting to engineer solutions to some of the more obvious areas of unmet need.

Medical Device

As TAVI Advances, Adjunctive Devices Multiply

As researchers work to more fully understand the risks and durability of transcatheter aortic heart valve implantation (TAVI) procedures, device innovators are already attempting to engineer solutions to some of the more obvious areas of unmet need.

Medical Device United States

Best of the Blog START-UP February 2009

A selection of our best blog posts from February for stories not covered elsewhere in the magazine includes: Friends in High Places: The White House appears to appreciate the need for innovation and, Medtronic's $1.03 billion buying spree is only the beginning in percutaneous heart valves.

Heart Valve Market: PAVR Poised for Growth

Much like the early days of coronary stenting, percutaneous aortic valve replacement has captured the imagination of physicians and industry alike. Although many challenges remain, most physicians in the heart valve community appear optimistic that transcatheter aortic valve technologies will eventually achieve a prominent place in the treatment armamentarium, a development that would put these devices on track to achieve over $1 billion in sales within the next five years.
Medical Device
See All

Company Information

  • Industry
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Heart Leaflet Technologies Inc.
  • Senior Management
  • Robert Wilson, MD, CEO
    Kem Schankerele, Dir., Valve Dev.
  • Contact Info
  • Heart Leaflet Technologies Inc.
    Phone: (763) 463-2060
    7351 Kirkwood Ln. N.
    Ste. 104
    Maple Grove, MN 55369
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register